Denosumab for post-transplantation hypercalcemia in osteopetrosis

New England Journal of Medicine

Volumn 367, Issue 18, 2012, Pages 1766-1767

  Shroff, Rukshana ^a   Beringer, Ortraud ^b   Rao, Kanchan ^a   Hofbauer, Lorenz C ^c   Schulz, Ansgar ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868247051     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1206193     Document Type: Letter

References (5)

1. Driessen GJ, Gerritsen EJ, Fischer A, et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. Bone Marrow Transplant 2003;32:657-63.
2. Martinez C, Polgreen LE, DeFor TE, et al. Characterization and management of hypercalcemia following transplantation for osteopetrosis. Bone Marrow Transplant 2010;45:939-44.
3. Pangrazio A, Cassani B, Guerrini MM, et al. RANK-dependent autosomal recessive osteopetrosis: characterisation of 5 new cases with novel mutations. J Bone Miner Res 2012;27:342-51.
4. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65. [Erratum, N Engl J Med 2009;361:1914.]
5. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9.